Combination therapy for stomach cancer spread to the abdomen
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of treatments for stomach cancer that has spread to the lining of the abdomen. It uses an immunotherapy drug (tislelizumab) with chemotherapy (SOX) and heated chemotherapy directly into the abdomen (HIPEC) to see if it works better than standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of stomach cancer called HER2-negative adenocarcinoma that has not been treated before.
- You are between 18 and 80 years old and your daily activity level is good (able to do light work).
- The cancer has spread only to the lining of the abdomen (peritoneal metastasis) and a score of how much it has spread (PCI) is 20 or less.
- Your blood counts and liver and kidney function are within certain healthy ranges.
- You are willing to provide blood and tissue samples and follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a treatment approach for stomach cancer that hasn't spread to other organs. It's for people who have not had any prior cancer treatments and are in relatively good health.
This study tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy (SOX) as a first treatment for locally advanced stomach or gastroesophageal junction cancer. It aims to see if this combination can help shrink the tumor before surgery.
This trial tests a combination of heated chemotherapy given directly into the belly (HIPEC), standard chemotherapy (SOX), and an immunotherapy drug (sintilimab) for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this triple therapy can shrink or control the cancer better than standard treatments.
This trial tests a combination of an immunotherapy drug (tislelizumab) and chemotherapy after surgery to prevent stomach cancer from coming back in older patients. It may be a good option for people who have had their cancer completely removed and are in good overall health.
This trial tests a new drug called BioTTT001 combined with chemotherapy (SOX) and another drug (toripalimab) for stomach cancer that has spread to the lining of the abdomen. It is for people who have not had treatment for advanced disease or whose cancer came back more than 6 months after earlier treatment.
This trial tests whether adding a drug called tislelizumab (an immunotherapy) to standard chemotherapy before and after surgery is better than chemotherapy alone for people with a specific type of stomach or GEJ cancer that has a high level of a marker called MHC class II. The goal is to see if it helps shrink the tumor and improves the chance of successful surgery.
Hear when a new Gastric Cancer with Peritoneal Metastasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.